Bibliography
- KARMAZYN M: Pharmacology and clinical assessment of cariporide for the treatment coronary artery diseases. Exp. Opin. Invest. Drugs (2000) 9:1099–1108.
- THE.ROUX P, CHAITMAN BR, DANCHIN N et al.: For the Guard During Ischemia Against Necrosis (GUARDIAN) investigators. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations — main results of the GUARDIAN trial. Circulation (2000) 102:3032–3038.
- ZEYMER U, SURYAPRANATA H, MONASSIER JP et al.: For the ES CAMI investigators. The Na±/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction - results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) Trial. J. Am. Coll. Cardiol (2001) 38:1644–1650.
- PFEFFER MA, McMURRAY JJV, VELAZQUEZ EJ et al.: For the valsartan in acute myocardial infarction trial investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl. I Med. (2003) 349:1893–1906.
- DICKSTEIN K, KJEKSHUS J: Effects oflosartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet (2002) 360:752–760.
- COHN JN, TOGNONI G: For the valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor inhibitor valsartan in chronic heart failure. N Engl. Med. (2001) 345:1667–1675.
- McMURRAY JJV, OSTERGREN J, SWEDBERG K et al.: For the CHARM investigators and committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:759–756.
- UNGER T: The ongoing telmisartan alone and in combination with ramipril global endpoint trial program [ONTARGET]. Am. J. Cardiol (2003) 91:28G–34G.
- NISSEN SE, TUZCU EM, SCHOENHAGEN P et al.: For the REVERSAL Investigators. Effects of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 291:1071–1080.
- CANNON CP, BRAUNWALD E, McCABE CH et al.: for the Pravastatin and Atorvastatin Evaluation and Infection Therapy -Thrombolysis in Myocardial Infarction 22 Investigators. Comparision of intensive and moderate lipid-lowering with statins after acute coronary syndromes. N. Engl. Med. (2004) 350(15) (Epub ahead of print).
- HALPERIN JL, EXECUTIVE STEERING COMMITTEE, SPORTIF III AND V STUDY INVESTIGATORS: Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline characteristics (SPORTIF III and V). Am. Heart .1. (2003) 146:431-438. Affiliation Bernhard R Winkelmann MD Head of Cooperation Unit Pharmacogenomics/ Applied Genomics, University of Heidelberg, 58 Bergheimer Street, 69115 Heidelberg, Germany Tel: +49 6221 56 4509; Fax: +49 6221 56 1331; E-mail: [email protected]